Adaptive Biotechnologies Corporation
ADPT
Helyezés a részvények között
#4020
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Részvényárfolyam
$25.63
Piaci kapitalizáció
$4.09B
Változás (1 nap)
4.95%
Változás (1 év)
47.72%
Ország
US
Kereskedés Adaptive Biotechnologies Corporation (ADPT)
Kategória
Healthcare
Bevétel a(z) Adaptive Biotechnologies Corporation (ADPT) részvényhez
Bevétel ekkor: Jun 2026 TTM: $308.08M
Adaptive Biotechnologies Corporation legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $308.08M. 2024 évben a vállalat $178.96M árbevételt ért el, amely növekedés a 2023 évben elért $170.28M árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Adaptive Biotechnologies Corporation bevételtörténete 2017 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $308.08M | 11.23% |
| 2025 | $276.98M | 54.77% |
| 2024 | $178.96M | 5.10% |
| 2023 | $170.28M | -8.11% |
| 2022 | $185.31M | 20.06% |
| 2021 | $154.34M | 56.88% |
| 2020 | $98.38M | 15.65% |
| 2019 | $85.07M | 52.83% |
| 2018 | $55.66M | 44.77% |
| 2017 | $38.45M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $12.62B | 3,997.72% |
US
|
|
| $2.23B | 623.19% |
US
|
|
| $15.74B | 5,010.45% |
AU
|
|
| $6.02B | 1,854.45% |
NL
|
|
| - | - |
CH
|
